» Articles » PMID: 16123085

Mullerian Inhibiting Substance Levels at the Time of HCG Administration in IVF Cycles Predict Both Ovarian Reserve and Embryo Morphology

Overview
Journal Hum Reprod
Date 2005 Aug 27
PMID 16123085
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pre-antral and early antral follicles secrete Müllerian inhibiting substance (MIS), suggesting that MIS may directly reflect ovarian reserve. Since little is known about how ovarian reserve affects oocyte quality, we attempt here to assess the predictive value of MIS on embryo morphology and IVF outcome. To do so, we measured MIS at the time of HCG administration 36 h prior to oocyte retrieval.

Methods: A total of 257 patients undergoing IVF were prospectively recruited. We measured MIS levels by enzyme-linked immunosorbent assay at the time of HCG, and compared the MIS values to day 3 FSH levels in the prediction of embryo morphology and IVF outcome.

Results: The distribution of MIS levels was skewed, with a median of 2.7 ng/ml (range 0 to 28.5 ng/ml). MIS values at the time of HCG administration inversely correlated with basal FSH levels (P = 0.002), and both correlated significantly with patient age, number of mature follicles, number of oocytes retrieved and serum estradiol levels. MIS levels correlated significantly with a greater number of 6-cell embryos and better embryo morphology score, while basal FSH levels did not correlate with these outcome variables. MIS levels > or =2.7 ng/ml portended improved oocyte quality as reflected in a higher implantation rate (P = 0.001) and a trend toward a better clinical pregnancy rate (P = 0.084).

Conclusions: MIS levels seem to predict not only ovarian reserve, but also embryo morphology. Measurement of MIS at the time of HCG administration may, therefore, in the future improve management of patients undergoing treatments with assisted reproductive technology.

Citing Articles

Association of Anti-Müllerian Hormone on Oocyte Maturation, Fertilization, and Pregnancy Rates in Patients under Assisted Reproductive Technology Cycles: A Cross-Sectional Study.

Ghiasi Hafezi S, Ghorbanzadeh M, Honarmand Rahaghi B, Rezvaniyan F, Forghani N, Shafiean M Int J Fertil Steril. 2024; 18(3):222-227.

PMID: 38973274 PMC: 11245587. DOI: 10.22074/ijfs.2023.1988282.1428.


A validated model for individualized prediction of pregnancy outcome in woman after fresh cycle of Day 5 single blastocyst transfer.

Chen L, Jiang R, Jiang Y, Su Y, Wang S Sci Rep. 2023; 13(1):10016.

PMID: 37340007 PMC: 10282095. DOI: 10.1038/s41598-023-36824-8.


Antimüllerian hormone (AMH) and age as predictors of preimplantation genetic testing for aneuploidies (PGT-A) cycle outcomes and blastocyst quality on day 5 in women undergoing in vitro fertilization (IVF).

Arnanz A, Bayram A, Elkhatib I, Abdala A, El-Damen A, Patel R J Assist Reprod Genet. 2023; 40(6):1467-1477.

PMID: 37145374 PMC: 10310637. DOI: 10.1007/s10815-023-02805-z.


Systematic review of acupuncture to improve ovarian function in women with poor ovarian response.

Wang R, Su M, Liu L, Lai Y, Guo X, Gan D Front Endocrinol (Lausanne). 2023; 14:1028853.

PMID: 36992800 PMC: 10040749. DOI: 10.3389/fendo.2023.1028853.


AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles.

Li H, Seifer D, Tal R Reprod Biol Endocrinol. 2023; 21(1):19.

PMID: 36739415 PMC: 9898926. DOI: 10.1186/s12958-023-01066-w.